Why the study?
Literature regarding the use of bivalirudin as an anticoagulation strategy for acute pediatric hemodialysis is very scarce.
Bivalirudin may serve as an alternative anticoagulation strategy for acute hemodialysis in pediatric patients when unfractionated heparin cannot be used.
Bivalirudin may serve as an alternative in select pediatric hemodialysis cases; case reports leave open the need for prospective safety and efficacy data.
Unfractionated heparin is the most used anticoagulative agent for extracorporeal settings in children, including acute hemodialysis modalities. In certain situations, such as heparin-induced thrombocytopenia, alternatives must be applied. The direct thrombin inhibitor bivalirudin has come forth as an attractive substitute. Bivalirudin is currently only approved for adult use in specific percutaneous coronary intervention settings. However, it has a growing off-label popularity in different contexts for both adult and pediatric patients. Experience with bivalirudin in children is mainly limited to extracorporeal membrane oxygenation, ventricular assist devices and during cardiopulmonary bypass surgery. Literature about its use as anticoagulation strategy for pediatric hemodialysis is very scarce. Here, we present two pediatric cases where bivalirudin was used during acute hemodialysis, followed by a short summary of recent literature.
No takes yet. Share an insight, caveat, or question.
Viaene et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Hemodialysis International